Posted by Michael Wonder on 07 Jul 2016
Proposal to award sole supply to goserelin acetate (Zoladex) and reference price leuprorelin acetate (Eligard and Lucrin PDS)
7 July 2016 - PHARMAC has entered into a provisional agreement with AstraZeneca.
PHARMAC is seeking feedback on a proposal to:
- Reduce the price and subsidy for AstraZeneca’s brand of goserelin acetate (Zoladex) from 1 October 2016.
- Award Sole Supply Status and Hospital Supply Status to AstraZeneca’s brand of goserelin acetate (Zoladex) from 1 December 2016
This means Zoladex would be the only fully funded brand of goserelin in the community and would be the only available brand in DHB hospitals subject to a 1% discretionary variance limit from 1 December 2016.
